In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.
Despite the challenges of completing this trial during the onset of the COVID-19 pandemic response, Veristat has collected and is now analyzing the study data.
Veristat will deliver top-line results of this study in six weeks as announced by Antibe Therapeutics.
Read the full press release on the Antibe Therapeutics website:
MEET VERISTAT - COMPLEXITY IS OUR SPECIALTY
We understand that the stakes are high, no matter where you are in your development program. The changing regulations and rapid speed with which clinical programs are changing during the COVID-19 pandemic response is overwhelming. We have the agility and scientific-minded experts to help you navigate these uncertain times. Get introduced to Veristat today.